BTG Consulting 

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through two segments, Product and Licensing. The company offers oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and cryoablation technology for use in kidney cancer. It also provides vascular products consisting of EKOS blood clot treatment devices; arterial blockage crossing devices; Varithena for the treatment of varicose veins; and sentry inferior vena cava filters. In addition, the company offers acute care products, such as CroFab, DigiFab, and Voraxaze. Further, it provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.